Journal of Shanghai Jiao Tong University (Medical Science) >

2023 , Vol. 43 >Issue 6: 747 - 754

DOI: https://doi.org/10.3969/j.issn.1674-8115.2023.06.011

Clinical research

Construction and validation of prognostic risk model for hepatocellular carcinoma based on biological analysis of palmitoyl-associated enzyme long-chain non-coding RNA

  • Li YU ,
  • Xiandu SU ,
  • Min ZHANG ,
  • Yahui LI ,
  • Le WANG
Expand
  • Clinical Laboratory, Danzhou People's Hospital, Hainan Province, Danzhou 571700, China
YU Li, E-mail: hhelong1123@163.com.

Received date: 2023-01-13

  Accepted date: 2023-04-03

  Online published: 2023-06-28

Fold

Abstract

Objective ·To explore the effect of screening the expression of long non-coding RNA (lncRNA) related to palmitoylation on prognosis of liver cancer based on The Cancer Genome Atlas (TCGA) database and construct a risk prediction model in liver cancer. Methods ·The sequencing data and the corresponding clinical information of 374 liver cancer tissues and 50 normal tissue samples were downloaded from TCGA database. The differential zinc finger aspartate-histidine-histidine-cysteine domain (ZDHHC) between liver cancer tissues and normal tissues was used to construct the expression profile of lncRNA related to ZDHHC. Furthermore, the prediction model was constructed by LASSO regression algorithm and the validity of the model prediction was verified to analyze the relationship between high-risk and low-risk groups and immune function and to predict the response to immunotherapy. Results ·There were 20 differentially expressed ZDHHCs in hepatocellular carcinoma, among which 656 lncRNAs were correlated with differential ZDHHCs (all P<0.05). Univariate COX analysis showed that 22 lncRNAs were associated with the prognosis of hepatocellular carcinoma (HR 1.47?13.05, all P<0.05), and LASSO regression analysis included 3 lncRNAs to construct a risk model. The risk score=0.662 6×AC026356.1+0.213 9×AC026401.3+0.405 6×POLH-AS1. In the model, the overall survival (OS) and progression-free survival (PFS) of patients in the high-risk group were significantly lower than those in the low-risk group (all P<0.05). Multivariate COX regression analysis showed that the model as a risk factor was an independent factor affecting survival (HR=1.375, 95%CI 1.208?1.566). In the risk model, there were significant differences between high-risk and low-risk immune function pathways, and the response level of high-risk patients to immunotherapy was lower (P<0.05). Conclusion ·The use of a risk model based on palm acylation related lncRNA expression can independently predict the survival period of liver cancer patients, providing reference for patients receiving immunotherapy.

Key words： hepatocellular carcinoma (HCC); long non-coding RNA (lncRNA); palmitoylation; risk model; immune therapy

Cite this article

Li YU , Xiandu SU , Min ZHANG , Yahui LI , Le WANG . Construction and validation of prognostic risk model for hepatocellular carcinoma based on biological analysis of palmitoyl-associated enzyme long-chain non-coding RNA[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023 , 43(6) : 747 -754 . DOI: 10.3969/j.issn.1674-8115.2023.06.011

References

1 黄飞虎, 余姣, 万谟彬. 肝细胞癌的筛查与监测[J]. 肝脏, 2021, 26(10): 1075-1077.
1 HUANG F H, YU J, WAN M B. Screening and monitoring of hepatocellular carcinoma[J]. Liver, 2021, 26(10): 1075-1077.
2 WANG Q H, XIA D D, BAI W, et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study[J]. J Hepatol, 2019, 70(5): 893-903.
3 肖姗姗, 李越, 周艳阳, 等. 基于TCGA数据库构建三阴性乳腺癌预后相关的ceRNA调控网络及分析[J]. 现代检验医学杂志, 2023, 38(1): 83-88, 106.
3 XIAO S S, LI Y, ZHOU Y Y, et al. Construction and analysis of ceRNA regulatory network related to prognosis of triple negative breast cancer based on TCGA database[J]. Journal of Modern Laboratory Medicine, 2023, 38(1): 83-88, 106.
4 XU Z J, PENG B, LIANG Q J, et al. Construction of a ferroptosis-related nine-lncRNA signature for predicting prognosis and immune response in hepatocellular carcinoma[J]. Front Immunol, 2021, 12: 719175.
5 LEMONIDIS K, WERNO M W, GREAVES J, et al. The zDHHC family of S-acyltransferases[J]. Biochem Soc Trans, 2015, 43(2): 217-221.
6 ZMUDA F, CHAMBERLAIN L H. Regulatory effects of post-translational modifications on zDHHC S-acyltransferases[J]. J Biol Chem, 2020, 295(43): 14640-14652.
7 SALAUN C, LOCATELLI C, ZMUDA F, et al. Accessory proteins of the zDHHC family of S-acylation enzymes[J]. J Cell Sci, 2020, 133(22): jcs251819.
8 FRASER N J, HOWIE J, WYPIJEWSKI K J, et al. Therapeutic targeting of protein S-acylation for the treatment of disease[J]. Biochem Soc Trans, 2020, 48(1): 281-290.
9 ZHOU B H, HAO Q Y, LIANG Y M, et al. Protein palmitoylation in cancer: molecular functions and therapeutic potential[J]. Mol Oncol, 2023, 17(1): 3-26.
10 YAO H, LI C S, HE F, et al. A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions[J]. RSC Chem Biol, 2021, 2(1): 192-205.
11 YANG Y, HSU J M, SUN L L, et al. Palmitoylation stabilizes PD-L1 to promote breast tumor growth[J]. Cell Res, 2019, 29(1): 83-86.
12 KINNEY N, VARGHESE R T, ANANDAKRISHNAN R, et al. ZDHHC3 as a risk and mortality marker for breast cancer in African American women[J]. Cancer Inform, 2017, 16: 1176935117746644.
13 LIU P, JIAO B, ZHANG R, et al. Palmitoylacyltransferase Zdhhc9 inactivation mitigates leukemogenic potential of oncogenic nras[J]. Leukemia, 2016, 30(5): 1225-1228.
14 REMSBERG J R, SUCIU R M, ZAMBETTI N A, et al. ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth[J]. Nat Chem Biol, 2021, 17(8): 856-864.
15 JIANG P, GU S Q, PAN D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response[J]. Nat Med, 2018, 24(10): 1550-1558.
16 YOKOI N, FUKATA Y, SEKIYA A, et al. Identification of PSD-95 depalmitoylating enzymes[J]. J Neurosci, 2016, 36(24): 6431-6444.
17 LIN H N. Protein cysteine palmitoylation in immunity and inflammation[J]. FEBS J, 2021, 288(24): 7043-7059.
18 CHEN X R, MA H H, WANG Z, et al. EZH2 palmitoylation mediated by ZDHHC5 in p53-mutant glioma drives malignant development and progression[J]. Cancer Res, 2017, 77(18): 4998-5010.
19 TANG F, YANG C, LI F P, et al. Palmitoyl transferases act as potential regulators of tumor-infiltrating immune cells and glioma progression[J]. Mol Ther Nucleic Acids, 2022, 28: 716-731.
20 LIU Z, LIU C, XIAO M M, et al. Bioinformatics analysis of the prognostic and biological significance of ZDHHC-protein acyltransferases in kidney renal clear cell carcinoma[J]. Front Oncol, 2020, 10: 565414.
21 FHU C W, ALI A. Protein lipidation by palmitoylation and myristoylation in cancer[J]. Front Cell Dev Biol, 2021, 9: 673647.
22 ZHANG Z X, LI X, YANG F, et al. DHHC9-mediated GLUT1 S-palmitoylation promotes glioblastoma glycolysis and tumorigenesis[J]. Nat Commun, 2021, 12(1): 5872.
Options
Outlines

/

〈 〉